ABSTRACT NUMBER: ESOC2026A555 VGLUT2-AUTOANTIBODIES-RELATED CEREBRAL VASCULITIS AND ENCEPHALITIS

Abstract Background and aims Antibodies against the vesicular glutamate transporter 2 (VGluT2) have recently been suggested to cause a new form of autoimmune disorder with predominant encephalitis, cognitive deficits and neuropathy. Only two cases of VGluT2-related encephalitis with cerebral vasculitis have so far been published [PMID: 40494504]. Methods Here, we describe the clinical manifestations and disease course of a patient with VGluT2-associated small vessel vasculitis. Results A 43-year-old woman presented with acute-onset auditory and visual hallucinations, memory impairment, confusion, gait instability, and ataxia. Her symptoms worsened progressively, and seizures emerged five months after onset. Workup showed encephalitis and cerebral small vessel vasculitis. Immunosuppressive therapy was then initiated, with high-dose methylprednisolone followed by long-term mycophenolate mofetil. In the following months, the symptoms gradually improved. At one year, the patient remained severely disabled, partial functional independence was regained by two years and improvement continued until 38 months. Twenty-one months after onset, the patient developed central artery occlusion in one eye. Serial brain magnetic resonance images revealed multiple inflammatory and ischemic lesions of varying ages across several vascular territories. There was no evidence of an embolic source or a prothrombotic disorder. Marked brain atrophy ensued. Cerebrospinal fluid analyses demonstrated early inflammatory and elevated neurofilament light chain levels, which improved but remained mildly increased at three years. VGluT2 autoantibodies persisted in serum with declining titers over time. Conclusions We describe the longitudinal clinical course of VGluT2-related encephalitis and cerebral vasculitis. VGluT2 antibodies should be analyzed in this clinical setting to detect this treatable disorder. Conflict of interest Andreea Ilinca: nothing to disclose

Authors

Institutions

Publication Details

Journal
European Stroke Journal
Published
2026-05-01
DOI
https://doi.org/10.1093/esj/aakag023.1348
Primary Topic
Autoimmune Neurological Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ABSTRACT NUMBER: ESOC2026A555 VGLUT2-AUTOANTIBODIES-RELATED CEREBRAL VASCULITIS AND ENCEPHALITIS

Andreas Puschman, Andreea Ilinca
European Stroke Journal
Autoimmune Neurological Disorders and Treatments
article

ABSTRACT NUMBER: ESOC2026A555 VGLUT2-AUTOANTIBODIES-RELATED CEREBRAL VASCULITIS AND ENCEPHALITIS

Andreas Puschman, Andreea Ilinca
article en

Abstract

Abstract Background and aims Antibodies against the vesicular glutamate transporter 2 (VGluT2) have recently been suggested to cause a new form of autoimmune disorder with predominant encephalitis, cognitive deficits and neuropathy. Only two cases of VGluT2-related encephalitis with cerebral vasculitis have so far been published [PMID: 40494504]. Methods Here, we describe the clinical manifestations and disease course of a patient with VGluT2-associated small vessel vasculitis. Results A 43-year-old woman presented with acute-onset auditory and visual hallucinations, memory impairment, confusion, gait instability, and ataxia. Her symptoms worsened progressively, and seizures emerged five months after onset. Workup showed encephalitis and cerebral small vessel vasculitis. Immunosuppressive therapy was then initiated, with high-dose methylprednisolone followed by long-term mycophenolate mofetil. In the following months, the symptoms gradually improved. At one year, the patient remained severely disabled, partial functional independence was regained by two years and improvement continued until 38 months. Twenty-one months after onset, the patient developed central artery occlusion in one eye. Serial brain magnetic resonance images revealed multiple inflammatory and ischemic lesions of varying ages across several vascular territories. There was no evidence of an embolic source or a prothrombotic disorder. Marked brain atrophy ensued. Cerebrospinal fluid analyses demonstrated early inflammatory and elevated neurofilament light chain levels, which improved but remained mildly increased at three years. VGluT2 autoantibodies persisted in serum with declining titers over time. Conclusions We describe the longitudinal clinical course of VGluT2-related encephalitis and cerebral vasculitis. VGluT2 antibodies should be analyzed in this clinical setting to detect this treatable disorder. Conflict of interest Andreea Ilinca: nothing to disclose

European Stroke JournalVol. 11(Supplement_1)
Lund University (SE), Skåne University Hospital (SE)
Good health and well-being
Openalex Percentile: Top 9%
Autoimmune Neurological Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.